Systolic Hypertension in Europe Placebo-Controlled Trial
NCT02088450
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
4695
Enrollment
OTHER
Sponsor class
Conditions
Isolated Systolic Hypertension
Interventions
DRUG:
Active treatment with nitrendipine (10-40 mg/day).
Sponsor
KU Leuven